Related Experiment Videos
Gastrointestinal cancer refractory to chemotherapy: a role for octreotide?
S Cascinu1, V Catalano, P Giordani
1Section of Experimental Oncology, Division of Medical Oncology, Azienda Ospedaliera S. Salvatore, Pesaro, Italy.
Abstract:
Although octreotide has been shown to inhibit the growth of gastrointestinal (GI) tumors in vitro and in vivo, preliminary clinical trials have reported disappointing results for this somatostatin analog in patients with GI cancers. The results of these trials probably reflect the difficulty in assessing the therapeutic potential of an agent such as octreotide in GI cancers. Thus, it is possible that treatment with octreotide could be useful in the stabilization of disease if it is associated with an improvement in survival. On the basis of these considerations five randomized trials were carried out to evaluate the therapeutic potential in patients with GI cancers. Four trials (one in patients with colorectal carcinoma and three in patients with carcinoma of the pancreas) did not show any advantage of octreotide in untreated patients; in contrast, one trial reported that octreotide prolonged survival in patients with GI cancers refractory to chemotherapy. Some clinical features of the latter study (treatment with chemotherapy, different schedules) may explain these conflicting results. Although data from randomized trials suggest that octreotide is not effective in untreated asymptomatic advanced GI cancer patients, further studies are warranted to assess the efficacy of octreotide in chemotherapy refractory patients in order to clarify the impact of octreotide in terms of not only survival but also on the patients' quality of life.
Insights
Octreotide did not improve outcomes for untreated gastrointestinal (GI) cancer patients. However, it may prolong survival in patients with advanced GI cancers refractory to chemotherapy, warranting further study.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Octreotide, a somatostatin analog, shows in vitro and in vivo inhibition of gastrointestinal (GI) tumor growth.
- Preliminary clinical trials reported disappointing results for octreotide in GI cancers.
- Assessing octreotide's therapeutic potential in GI cancers presents challenges.
Purpose of the Study:
- To evaluate the therapeutic potential of octreotide in patients with GI cancers.
- To determine if octreotide stabilizes disease and improves survival.
- To investigate octreotide's efficacy in different patient populations and treatment settings.
Main Methods:
- Five randomized trials were conducted.
- Trials included patients with colorectal carcinoma and carcinoma of the pancreas.
- Patient populations varied, including untreated patients and those refractory to chemotherapy.
Main Results:
- Four trials showed no advantage of octreotide in untreated patients.
- One trial reported prolonged survival in GI cancer patients refractory to chemotherapy.
- Conflicting results may be due to differences in chemotherapy treatment and schedules.
Conclusions:
- Octreotide is not effective in untreated asymptomatic advanced GI cancer patients.
- Further studies are needed to assess octreotide's efficacy in chemotherapy-refractory patients.
- The impact of octreotide on survival and quality of life requires further clarification.